Phathom Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
Menlo Park, Calif., June 4, 2019 – Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders, today announced that David Socks, Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019 at 2:00 p.m. ET in New York, NY.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late stage development for the treatment of acid-related disorders. In May 2019, the company completed a $50 million term loan facility from Silicon Valley Bank and a $90 million private financing from investors including Frazier Healthcare Partners, Medicxi, RA Capital Management, Abingworth, certain accounts managed by Janus Henderson Investors, BVF Partners LP, Greenspring Associates, Richard King Mellon Foundation, Sahsen Ventures and additional undisclosed institutional investors. For more information about Phathom, visit the company’s website at www.phathompharma.com.